Unsubstantiated claims against incretin drugs draw fiery response

August 9, 2013, Mary Ann Liebert, Inc

The conclusions reached by the authors of a recent autopsy study stating that incretin-based drugs to treat diabetes can increase the risk of pancreatic cancer are overstated and unnecessarily alarmist, according to a Critique published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The Critique is available free on the DTT website at www.liebertpub.com/dia.

Important differences between the two groups of patients studied were overlooked, leading to irresponsible claims made against two effective classes of glucose-lowering drugs used by millions of people with , say Evis Harja, MD, Jonathan Lord, MD, and Jay Skyler, MD, University of Miami Miller School of Medicine (Florida). They identify specific flaws in the design and analysis of the study by Butler et al. (Diabetes 2013;62:2595–2604).

In the Critique, "An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology," the authors point out the "clear and unambiguous difference between the [diabetes mellitus] DM-incretin and DM-other groups." Furthermore, "the beneficial clinical effects of the incretin drugs were ignored" and claims of potential harm were made with the intent to create controversy rather than to represent the facts.

"Incretin drugs can yield significant improvement in glucose control without causing hypoglycemia, and are associated with an improved lipid profile and either no weight gain or even weight loss, which are important outcomes for patients with diabetes," says Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver. "These therapeutic agents are widely used in clinical practice. The database available to judge their effects on the pancreas is small, and claims that they are harmful are unsubstantiated. Large, ongoing studies will lead to more definitive conclusions."

These studies were made possible through tissues obtained from the Network for Pancreatic donors with Diabetes (nPOD). nPOD is a multi-national collaborative investigation funded by JDRF and is designed to further scientific understanding of the causes of type 1 diabetes. "nPOD has been organized to help investigators have access to tissue samples that are normally difficult to obtain, but may prove beneficial to studies of diabetes," said Mark Atkinson, PhD, nPOD Director and Professor of Pathology at the University of Florida. "We are proud to support, free of charge, well over 100 projects with that goal and look forward to seeing additional research that will bring clarity to this question."

Explore further: Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans

More information: Harja, E., Lord, J. and Skyler, J. An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology, Diabetes Technology & Therapeutics, August 8, 2013. DOI: 10.1089/dia.2013.0177.

Related Stories

Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans

March 27, 2013
(Medical Xpress)—Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine ...

How can advanced imaging studies enhance diabetes management?

May 13, 2013
New approaches to applying noninvasive imaging tests such as computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) may play a bigger role in evaluating and managing patients with diabetes. ...

New guidelines for standardizing glucose reporting and optimizing clinical decision making in diabetes

March 1, 2013
Most adults and children with type 1 diabetes are not in optimal glycemic control, despite advances in insulin formulations and delivery systems and glucose monitoring approaches. Critical barriers to optimal glycemic control ...

Understanding pancreas size may help unlock cause of Type 1 diabetes

December 12, 2012
(Medical Xpress)—People at risk for Type 1 diabetes may have fewer insulin-producing "beta" cells than people not at risk, a finding that could help researchers shed light on what causes the disease, a new University of ...

Researchers identify pivotal immune cell in Type 1 diabetes in humans

January 12, 2012
(Medical Xpress) -- Researchers at the La Jolla Institute for Allergy & Immunology have proven – for the first time in human tissues -- the specific immune system T cells which trigger the destruction of type 1 diabetes ...

Is there a link between mood and glucose control in diabetes?

May 2, 2012
When blood sugar levels in diabetes are poorly controlled, patients tend to have more complications such as depression and other mood disturbances, including anxiety and anger, and a lower overall quality of life. A better ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Thirty-year study shows women who breastfeed for six months or more reduce their diabetes risk

January 16, 2018
In a long-term national study, breastfeeding for six months or longer cuts the risk of developing type 2 diabetes nearly in half for women throughout their childbearing years, according to new Kaiser Permanente research published ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.